Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipovaxin Tuberculosis Vaccine in Healthy Adults in Indonesia
NCT07647107Phase 1Not yet recruiting
- Sponsor
- Bio Farma
- Start
- Aug 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LipovaksinS4-EAH in Tuberculosis (TB) (3 arms), sponsored by Bio Farma. Primary endpoints: Local and systemic reactions at 28 days, Adverse Events and Serious Adverse Events at 6 months and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
LipovaksinS4-EAH
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07647107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647107.